

Xue Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8506524/publications.pdf>

Version: 2024-02-01

28
papers

496
citations

758635

12
h-index

713013

21
g-index

32
all docs

32
docs citations

32
times ranked

794
citing authors

#	ARTICLE	IF	CITATIONS
1	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 892-901.	3.2	80
2	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , 2016, 7, 20810-20824.	0.8	73
3	First-in-Humans Evaluation of a PD-L1-Targeting Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 536-542.	2.8	56
4	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018, 18, 1171.	1.1	22
5	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , 2020, 20, 666.	1.1	22
6	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , 2019, 10, 2088-2095.	0.8	20
7	Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. <i>Clinical Lung Cancer</i> , 2020, 21, e258-e260.	1.1	17
8	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020, 10, 626.	1.3	17
9	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021, 10, 981-994.	1.3	17
10	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
11	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019, 10, 459-471.	0.8	14
12	Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 553-560.	0.7	13
13	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , 2020, 145, 140-143.	0.9	13
14	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019, 10, 1193-1202.	0.8	12
15	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020, 20, 793.	1.1	12
16	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 2081-2087.	0.8	11
17	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	0.8	10
18	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019, 10, 1788-1797.	0.8	10

#	ARTICLE	IF	CITATIONS
19	The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 3581-3592.	1.3	10
20	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 1149-1159.	0.8	8
21	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1137.	1.3	7
22	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 639892.	1.6	7
23	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 291-297.	0.8	5
24	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021, 11, 690093.	1.3	5
25	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage IIIA non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2021, 13, 1799-1812.	0.6	4
26	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021, 13, 1813-1821.	0.6	3
27	Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review. <i>Thoracic Cancer</i> , 2021, 12, 391-396.	0.8	2
28	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020, 20, 590.	1.8	0